论文部分内容阅读
目的:评价麦滋林联合弥可保预防XE-LOX化疗中的毒性反应。方法:对60例应用XE-LOX方案联合化疗病人随机分为两组,每组30例,治疗组于第1天化疗开始前予以弥可保针剂0.5mg静注,连续7日,观察神经毒性的发生率,同时口服麦滋林0.67g,每日3次连续14日,观察腹泻发生率。结果:治疗组奥沙利铂神经毒性发生率为16.7%(5/30),对照组43.3%(13/30),经秩和检验,差异有差异性(P<0.05),治疗组麦滋林腹泻发生23.3%(7/30)对照组发生率50%(15/30),经秩和检验有差异性(P<0.05)。结论:麦滋林联合弥可保对XELOX方案引起的腹泻及神经毒性有较好的防治作用。
OBJECTIVE: To evaluate the combination of mezlocin and methycobal in the prevention of toxic reactions in XE-LOX chemotherapy. Methods: Sixty patients undergoing combined chemotherapy with XE-LOX regimen were randomly divided into two groups (n = 30 in each group). The treatment group was given 0.5 mg intravenous injection of Mi-gui preservative before the start of chemotherapy on the first day for 7 consecutive days to observe the neurotoxicity The incidence of oral malzin 0.67g, 3 times a day for 14 consecutive days to observe the incidence of diarrhea. Results: The incidence of oxaliplatin neurotoxicity was 16.7% (5/30) in the treatment group and 43.3% (13/30) in the control group, and the difference was significant (P <0.05) Lindian diarrhea occurred in 23.3% (7/30) control group, the incidence of 50% (15/30), by rank sum test were different (P <0.05). Conclusion: The combination of mezloc and mifeprist can prevent diarrhea and neurotoxicity caused by XELOX regimen.